Related references
Note: Only part of the references are listed.Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'
Stefan Boeck et al.
ANTI-CANCER DRUGS (2010)
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Sanja Dacic et al.
MODERN PATHOLOGY (2010)
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials
J. P. Neoptolemos et al.
BRITISH JOURNAL OF CANCER (2009)
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma
A. Van den Broeck et al.
EJSO (2009)
Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin
Fiona Campbell et al.
HISTOPATHOLOGY (2009)
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma
Philip Bao et al.
HPB (2009)
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-lnstitution phase II study
David C. Linehan et al.
ANNALS OF SURGERY (2008)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
Chandrajit P. Raut et al.
ANNALS OF SURGERY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience
Jordan M. Winter et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2006)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
ErbB-targeted therapeutic approaches in human cancer
CL Arteaga
EXPERIMENTAL CELL RESEARCH (2003)
Epidermal growth factor receptor-targeted therapy for pancreatic cancer
HQ Xiong et al.
SEMINARS IN ONCOLOGY (2002)
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial
JP Neoptolemos et al.
ANNALS OF SURGERY (2001)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Share Paper
